Versions :<12345678Live>
Snapshot 6:Tue, Dec 9, 2025 5:24:51 PM GMT last edited by Haakan

Gene-Edited Therapy Achieves 82% Remission in Leukaemia Trial

Gene-Edited Therapy Achieves 82% Remission in Leukaemia Trial

Above: Alyssa Tapley, accompanied by her family, attended the 2025 Breakthrough Prize Ceremony at Barker Hangar in Santa Monica, California, on April 5, 2025. She is notable for being the first person worldwide to receive the pioneering leukemia treatment. Image credit: Craig T Fruchtman/Contributuor/Getty Images

The Spin

Gene-edited therapy BE-CAR7 represents a monumental breakthrough in cancer treatment, achieving 82% deep remission rates for previously incurable T-cell leukemia. This off-the-shelf treatment uses base editing to transform donor immune cells into cancer-fighting weapons, offering real hope where only palliative care existed before.

While BE-CAR7 shows promise, the reality remains sobering: only 64% of patients remain disease-free, and outcomes were not as hoped for some children in these intense, difficult treatments. The therapy requires wiping out the entire immune system, leaving patients vulnerable to life-threatening infections during recovery.

Metaculus Prediction

There is a 50% chance the average survival rate of all cancers will exceed 75% by Dec. 2030, according to the Metaculus prediction community.


Articles on this story



© 2025 Improve the News Foundation. All rights reserved.Version 6.18.0

© 2025 Improve the News Foundation.

All rights reserved.

Version 6.18.0